Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study

K Puaprasert, C Chu, N Saralamba, NPJ Day, F Nosten… - Malaria Journal, 2018 - Springer
Background Plasmodium vivax malaria is characterized by relapses arising from the
hypnozoite stages in the liver. The only currently registered drug for radical treatment to …

CYP2D6 gene resequencing in the Malagasy, a population at the crossroads between Asia and Africa: a pilot study

ER Chan, RK Mehlotra, KA Pirani… - …, 2022 - Taylor & Francis
Background: Plasmodium vivax malaria is endemic in Madagascar, where populations have
genetic inheritance from Southeast Asia and East Africa. Primaquine, a drug of choice for …

CYP2D6 Genetic Variation and Its Implication for Vivax Malaria Treatment in Madagascar

RK Mehlotra, A Gaedigk, RE Howes… - Frontiers in …, 2021 - frontiersin.org
Plasmodium vivax is one of the five human malaria parasite species, which has a wide
geographical distribution and can cause severe disease and fatal outcomes. It has the ability …

Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function

A Martin Ramírez, C Lombardia González… - Malaria Journal, 2020 - Springer
Background Plasmodium vivax malaria is characterized by the presence of dormant liver-
stage parasites, called hypnozoites, which can cause malaria relapses after an initial attack …

The association of CYP2D6 gene polymorphisms in the full-length coding region with higher recurrence rate of vivax malaria in Yunnan Province, China

H Huang, Y Dong, Y Xu, Y Deng, C Zhang, S Liu… - Malaria Journal, 2021 - Springer
Background Accumulating evidence suggest that compromised CYP2D6 enzyme activity
caused by gene mutation could contribute to primaquine failure for the radical cure of vivax …

CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study

LW Brasil, F Rodrigues-Soares, AB Santoro… - Malaria journal, 2018 - Springer
Background CYP2D6 pathway mediates the activation of primaquine into active metabolite
(s) in hepatocytes. CYP2D6 is highly polymorphic, encoding CYP2D6 isoforms with normal …

Association of impaired cytochrome P450 2D6 activity genotype and phenotype with therapeutic efficacy of primaquine treatment for latent Plasmodium vivax malaria

JK Baird, M Louisa, R Noviyanti, L Ekawati… - JAMA Network …, 2018 - jamanetwork.com
Importance Latent hepaticPlasmodium vivaxhypnozoites provoke repeated clinical attacks
called relapses. Only primaquine phosphate kills hypnozoites, and its therapeutic activity …

Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients

S Choi, H Choi, SY Park, YG Kwak, JE Song, SY Shin… - Malaria Journal, 2022 - Springer
Background Primaquine is activated by CYP2D6 in the hepatocytes. In Korea, primaquine is
the only hypnozoitocidal agent used for patients with vivax malaria. Thus, patients with poor …

Genetic Variation of G6PD and CYP2D6: Clinical Implications on the Use of Primaquine for Elimination of Plasmodium vivax

AGA Stewart, PA Zimmerman… - Frontiers in …, 2021 - frontiersin.org
Primaquine, an 8-aminoquinoline, is the only medication approved by the World Health
Organization to treat the hypnozoite stage of Plasmodium vivax and P. ovale malaria …

[HTML][HTML] Prevalence of CYP2D6 genotypes and predicted phenotypes in a cohort of Cambodians at high risk for infections with Plasmodium vivax

MD Spring, C Lon, S Sok, D Sea… - The American Journal …, 2020 - ncbi.nlm.nih.gov
Clinical failure of primaquine (PQ) has been demonstrated in people with CYP450 2D6
genetic polymorphisms that result in reduced or no enzyme activity. The distribution of …